Jin-Hee Kim as New Representative Director (C) Santen Korea
SEOUL – Santen Korea, a leading global pharmaceutical company specializing in ophthalmology, announced on April 1st the appointment of Jin-Hee Kim as its new Representative Director. Kim, who previously served as the Head of Korea Business, takes the helm at a pivotal moment as the company seeks to solidify its dominance in the Asian eye care market.
A Career Built on Growth and Strategic Vision
Kim’s journey with Santen Korea is a testament to internal talent cultivation and long-term strategic contribution. Joining the company in April 2008 as a marketing specialist, she has been a fixture in the organization for nearly two decades. In 2010, she played a foundational role in transitioning Santen Korea to a direct sales business model, a move that fundamentally altered the company’s trajectory in the region.
Throughout her tenure, Kim has been instrumental in the successful launch and growth of various blockbuster products, particularly in the glaucoma segment. Her leadership was a driving force behind several high-profile corporate milestones, including:
Portfolio Expansion: Overseeing the transfer of sales rights for MSD’s ophthalmic products.
Strategic Partnerships: Facilitating the recent exclusive distribution and promotion agreement with Novartis Korea for their retina portfolio.
Regional Leadership: Serving as the Head of Asia Marketing from 2019 to 2023, where she sharpened the brand’s competitive edge across diverse markets.
Commitment to Patient-Centric Innovation
In her inaugural statement, Kim emphasized a balance between corporate growth and social responsibility.
"Based on the experience I have accumulated across the Korean and Asian business landscapes, I am committed to realizing patient-centered value creation alongside sustainable growth," Kim stated. "Through close collaboration with our employees, I will do my utmost to ensure Santen Korea leaps forward as a more trusted leader in the specialized field of ophthalmology."
Industry analysts view Kim’s appointment as a signal that Santen intends to deepen its localization strategy while leveraging her extensive regional expertise to integrate Korean operations more closely with the broader Asian market.
Key Executive Reshuffle
The appointment of Kim was part of a broader executive reorganization effective this April, aimed at strengthening the company’s strategic planning and future-readiness. Alongside the new Representative Director, Santen Korea announced two other key appointments:
Hye-Mi Jeong has been appointed as the Head of the Strategy Division.
Hye-Kyung Choi has been named the Head of the New Business Planning Department.
These appointments suggest a focused effort by Santen Korea to diversify its business interests beyond traditional eye drops, potentially looking toward digital health and advanced retinal therapies.
About Santen Korea
Santen Korea is the local subsidiary of Santen Pharmaceutical Co., Ltd., a global company founded in Japan. With a singular focus on ophthalmology, the company provides a wide range of treatments for glaucoma, dry eye, and retinal diseases. Under the new leadership of Jin-Hee Kim, the company is expected to accelerate its mission of "Happiness with Sight" by bringing innovative treatments to the Korean medical community.
[Copyright (c) Global Economic Times. All Rights Reserved.]
